Search results
Results From The WOW.Com Content Network
Sacituzumab govitecan was added to the proposed International nonproprietary name (INN) list in 2015, [26] and to the recommended list in 2016. [27] Sacituzumab govitecan-hziy was approved for medical use in the United States in April 2020. [12] [13] [14] [28] [11]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
An International Nonproprietary Name (INN) is an official generic and nonproprietary name given to a pharmaceutical substance or an active ingredient, [1] encompassing compounds, peptides and low-molecular-weight proteins (e.g., insulin, hormones, cytokines), as well as complex biological products, such as those used for gene therapy. [2]
List of proposed national monuments of the United States; V. Expansion of the Australian Football League This page was last edited on 22 February 2022, at 16:11 ...
Emibetuzumab (INN [1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. [2] It is in phase II trials for patients with NSCLC [3] This drug was developed by Eli Lilly & Company.
Lifastuzumab vedotin (INN; [1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer. [ 2 ] This drug was developed by Genentech / Roche .
Duvortuxizumab (INN [1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies. [ 2 ] This drug was developed by Janssen Global Services.
A phase 2 clinical trial for acute myeloid leukemia (AML) [4] was terminated early ("failed") in 2017. [5]It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), [6] but it may be abandoned.